Premier Asset Management LLC cut its stake in shares of Sanofi (NYSE:SNY) by 12.0% during the second quarter, Holdings Channel reports. The institutional investor owned 18,846 shares of the company’s stock after selling 2,564 shares during the period. Premier Asset Management LLC’s holdings in Sanofi were worth $902,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in SNY. Fisher Asset Management LLC increased its position in Sanofi by 8.1% in the second quarter. Fisher Asset Management LLC now owns 13,638,458 shares of the company’s stock valued at $653,419,000 after buying an additional 1,022,953 shares in the last quarter. Wells Fargo & Company MN increased its position in Sanofi by 22.2% in the first quarter. Wells Fargo & Company MN now owns 4,492,719 shares of the company’s stock valued at $203,296,000 after buying an additional 815,820 shares in the last quarter. Global Financial Private Capital LLC bought a new position in Sanofi during the first quarter valued at about $35,034,000. Karp Capital Management Corp bought a new position in Sanofi during the first quarter valued at about $26,174,000. Finally, Bank of America Corp DE increased its position in Sanofi by 8.2% in the first quarter. Bank of America Corp DE now owns 7,531,334 shares of the company’s stock valued at $340,792,000 after buying an additional 572,652 shares in the last quarter. Institutional investors own 9.90% of the company’s stock.
Shares of Sanofi (SNY) opened at 47.55 on Monday. The firm has a market cap of $119.42 billion, a P/E ratio of 11.23 and a beta of 0.88. Sanofi has a 52 week low of $36.81 and a 52 week high of $50.24. The stock’s 50 day moving average is $47.99 and its 200 day moving average is $46.11.
Sanofi (NYSE:SNY) last announced its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.74. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The business had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.71 billion. The company’s quarterly revenue was down 2.3% on a year-over-year basis. On average, equities research analysts predict that Sanofi will post $3.26 earnings per share for the current fiscal year.
Several equities analysts have issued reports on SNY shares. Zacks Investment Research downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Tuesday, April 25th. TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a research note on Monday, April 24th. BidaskClub upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Argus upped their price objective on shares of Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, June 9th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a research note on Thursday, April 20th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $63.75.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.